Cart
Compound Libraries Disease Focused

Disease Focused

These include focused libraries of small-molecule compounds with potential biological activity towards certain diseases (such as Anti-Cancer Compound Library, Anti-Diabetic Compound Library, Anti-Cardiovascular Disease Compound Library, etc.).

Cat No. product name
L1800 Anti-infection Compound Library A unique collection of 1326 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc; 1326 compounds
L2130 Anti-cancer Metabolism Compound Library A unique collection of 1072 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS); 1072 compounds
T002-00000003 Anti-Parkinson's Disease Compound Library 184 compounds
L4510 Anti-Parasite Library Quantity: 358 well-chosen unique anti-parasitic small molecules; 358 compounds
T002-00000002 Anti-Alzheimer's Disease Compound Library 650 compounds
L5200 Anti-Metabolism Disease Compound Library A unique collection of 1471 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS); 1471 compounds
L4520 Antibacterial Activity Library A unique collection of 1074 antibacterial bioactive compounds, a powerful tool for antibacterial drug development; 1074 compounds
L1718 X Domain-Targeted compound library (CADD) A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 463 compounds
L2170 Small Molecule Immuno-Oncology Compound Library A unique collection of 340 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening; 340 compounds
L4500 Antifungal Compound Library A unique collection of 157 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation. 157 compounds
L2190 Anti-Lung Cancer Compound Library A unique collection of 704 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study; 704 compounds
L1711 Anti-COVID-19 compound library (CADD) A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 362 compounds
L1719 nsp15-Targeted compound library (CADD) A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 470 compounds
L1714 RBD-Targeted compound library (CADD) A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 206 compounds
L2140 Promoting Cancer Cell Differentiation Compound Library A unique collection of 251 cancer cell differentiation inducing compounds for high throughput and high content screening; 251 compounds
T002-00000007 Anti-fibrosis Compound Library 981 compounds
L2180 Anticancer Library Plus Quantity: well-chosen 958 anti-tumor compounds with unique structures; 958 compounds
L1716 PLpro-Targeted compound library (CADD) A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 474 compounds
L2120 Anti-cancer Clinical Compound Library A unique collection of 1776 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS); 1776 compounds
L7100 Anti-obesity Compound Library A unique collection of 1176 anti-obesity compounds for high throughput and high content screening; 1176 compounds
L2150 Anti-cancer Drug library A unique collection of 822 anticancer drugs for high throughput screening (HTS) and high content screening (HCS); 2217 compounds
L2620 Neurodegenerative disease-related Compound Library A unique collection of 902 compounds related to neurodegenerative diseases can be used for HTS or HCS; 902 compounds
L4700 Immunology/Inflammation Compound Library A unique collection of 2769 anti-inflammation compounds effective for high throughput screening and high content screening. 2769 compounds
L8400 Hematonosis Compound Library A unique collection of 126 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS); 126 compounds
L1710 Anti-COVID-19 Compound Library A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents; 2448 compounds
L1715 nsp16-Targeted compound library (CADD) A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 281 compounds
L1900 Anti-diabetic Compound Library A unique collection of 468 diabetes related compounds; 468 compounds
L5400 Anti-Cardiovascular Disease Compound Library A unique collection of 987 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS); 987 compounds
L2191 Anti-Breast Cancer Compound Library 1052 compounds
L1700 Anti-virus Compound Library Quantity: A unique collection of 681 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening; 681 compounds
L2110 Anti-cancer Approved drug Library A unique collection of 1400 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS); 1400 compounds
L4660 Nervous system disease Library Quantity: well-chosen 935 compounds with unique structures targeting nervous system; 935 compounds
L2160 Anti-cancer Active Compound library A unique collection of 1656 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); 1656 compounds
L1712 3CLpro-Targeted compound library (CADD) A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 161 compounds
L2100 Anti-cancer Compound Library A unique collection of 4730 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); 4730 compounds
L2192 Anti-Pancreatic Cancer Compound Library 1162 compounds
L1717 RdRP-Targeted compound library (CADD) A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 464 compounds
L4710 Nonsteroidal Antiinflammatory Compound Library 530 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening. 530 compounds
L7110 Antihypertensive Compound Library 524 compounds
L1713 ACE2-Targeted compound library (CADD) A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; 462 compounds
Anti-infection Compound Library
L1800 compounds - 1326
Anti-cancer Metabolism Compound Library
L2130 compounds - 1072
Anti-Parkinson's Disease Compound Library
T002-00000003 compounds - 184
Anti-Parasite Library
L4510 compounds - 358
Anti-Alzheimer's Disease Compound Library
T002-00000002 compounds - 650
Anti-Metabolism Disease Compound Library
L5200 compounds - 1471
Antibacterial Activity Library
L4520 compounds - 1074
X Domain-Targeted compound library (CADD)
L1718 compounds - 463
Small Molecule Immuno-Oncology Compound Library
L2170 compounds - 340
Antifungal Compound Library
L4500 compounds - 157
Anti-Lung Cancer Compound Library
L2190 compounds - 704
Anti-COVID-19 compound library (CADD)
L1711 compounds - 362
nsp15-Targeted compound library (CADD)
L1719 compounds - 470
RBD-Targeted compound library (CADD)
L1714 compounds - 206
Promoting Cancer Cell Differentiation Compound Library
L2140 compounds - 251
Anti-fibrosis Compound Library
T002-00000007 compounds - 981
Anticancer Library Plus
L2180 compounds - 958
PLpro-Targeted compound library (CADD)
L1716 compounds - 474
Anti-cancer Clinical Compound Library
L2120 compounds - 1776
Anti-obesity Compound Library
L7100 compounds - 1176
Anti-cancer Drug library
L2150 compounds - 2217
Neurodegenerative disease-related Compound Library
L2620 compounds - 902
Immunology/Inflammation Compound Library
L4700 compounds - 2769
Hematonosis Compound Library
L8400 compounds - 126
Anti-COVID-19 Compound Library
L1710 compounds - 2448
nsp16-Targeted compound library (CADD)
L1715 compounds - 281
Anti-diabetic Compound Library
L1900 compounds - 468
Anti-Cardiovascular Disease Compound Library
L5400 compounds - 987
Anti-Breast Cancer Compound Library
L2191 compounds - 1052
Anti-virus Compound Library
L1700 compounds - 681
Anti-cancer Approved drug Library
L2110 compounds - 1400
Nervous system disease Library
L4660 compounds - 935
Anti-cancer Active Compound library
L2160 compounds - 1656
3CLpro-Targeted compound library (CADD)
L1712 compounds - 161
Anti-cancer Compound Library
L2100 compounds - 4730
Anti-Pancreatic Cancer Compound Library
L2192 compounds - 1162
RdRP-Targeted compound library (CADD)
L1717 compounds - 464
Nonsteroidal Antiinflammatory Compound Library
L4710 compounds - 530
Antihypertensive Compound Library
L7110 compounds - 524
ACE2-Targeted compound library (CADD)
L1713 compounds - 462